Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has successfully completed the full circulation of its H shares, with the conversion process concluding on September 17, 2024, and trading set to begin on September 19, 2024. This move involves 1,157,778 domestic and unlisted foreign shares, representing about 0.52% of the company’s total share capital. Shareholders and potential investors are advised to exercise caution when dealing with the company’s securities.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.